Are you Dr. Wegener?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
22 Stanfield Ave
Broomall, PA 19008Phone+1 610-353-4738
Summary
- Dr. William Wegener, MD is a board certified nuclear medicine physician in Broomall, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and New Jersey.
Education & Training
- Drexel University College of Medicine/Hahnemann University HospitalResidency, Radiology-Diagnostic, 1990 - 1991
- University of Pennsylvania Health SystemResidency, Nuclear Medicine, 1988 - 1990
- Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1987 - 1988
- University of Miami Leonard M. Miller School of MedicineClass of 1987
Certifications & Licensure
- PA State Medical License 1990 - 2024
- NJ State Medical License 2002 - 2019
- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1997 Mar 01
- Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Start of enrollment: 1997 Mar 01
- Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Start of enrollment: 2000 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 133 citationsCombination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's LymphomaJohn P. Leonard, Morton Coleman, Jamie C. Ketas, Michelle Ashe, J. M. Fiore
Journal of Clinical Oncology. 2005-08-01 - 118 citationsHumanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II ResultsFranck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, Marie Odile Petillon
Journal of Clinical Oncology. 2009-07-10 - 199 citationsFirst-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi
Clinical Cancer Research. 2015-05-05